ATHLONE, Ireland, May 24, 2016 (GLOBE NEWSWIRE) -- Innocoll (NASDAQ: INNL ), a global, commercial-stage, specialty pharmaceutical company, today announced that the Company will host a live webcast and conference call to review top-line results of its two, identical Phase 3 studies of XaraColl® (bupivacaine-collagen bioresorbable implant) for the treatment of postoperative pain relief immediately following open abdominal hernia repair.
The webcast and call will take place on Wednesday, May 25, 2016 at 8:30 AM Eastern Daylight Time. A press release announcing the top-line results will be issued prior to the webcast. Interested parties may access the webcast through the Investors section of our website or directly through the registration link .
About Innocoll Innocoll is a global, commercial-stage, specialty pharmaceutical company that is dedicated to engineering better medicines. Our proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use. Applied locally to wound and/or surgery sites, they are designed to provide a range of benefits. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColL for the treatment of postoperative pain; INL-002, a gentamicin-collagen topical matrix for the adjuvant treatment of diabetic foot infections; and INL-003, a collagen barrier for the prevention of post-surgical adhesions.
Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are sold globally through strategic partnerships, including those with Takeda, EUSA Pharma, Pioneer, Biomet 3i and Biomet. All of our native collagen products—from extraction/purification of type-1 collagen through final delivery form—are manufactured at our certified, integrated plant in Saal, Germany.
For more information, please visit www.innocoll.com .
Corporate: Pepe Carmona Chief Financial Officer (215) 983-3362 pcarmona@innocoll.com Jeannie Sorenson, M.D. Vice President, Investor Relations (314) 458-7355 jsorenson@innocoll.com